Results 181 to 190 of about 348,994 (265)

Protective immunity against Chagas disease induced by a superantigen-based chimeric DNA vaccine delivered by attenuated <i>Salmonella</i>. [PDF]

Front Immunol
Antonoglou MB, Sánchez Alberti A, Redolfi DM, Bivona AE, Noli Truant S, Sarratea MB, Cardoso A, Motta FN, Malchiodi EL, Fernández MM.   +9 more
europepmc   +1 more source

Anti‐CD19 CAR T Cells in Autoimmune Encephalitis: Inflammation Controlled, Neurodegeneration Unchecked?

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Just recently, successful chimeric antigen receptor (CAR) T cell therapy was reported in the first patient with refractory, anti‐diacylglycerol lipase alpha (DAGLA) antibody‐mediated autoimmune encephalitis, achieving partial clinical remission.
Dimitrios Mougiakakos, Marwa Al‐Dubai, Denise Walther, Dominic Borie, Jan D. Lünemann, Marc Pawlitzki, Sven G. Meuth, Solveig Henneicke, Stefan Vielhaber, Stefanie Schreiber   +9 more
wiley   +1 more source

The role of mucosal immune dysregulation in the pathogenesis of immunoglobulin A nephropathy. [PDF]

Front Immunol
Ohyama Y, Tsuji Y, Tezuka H, Novak J, Takahashi K.   +4 more
europepmc   +1 more source

Recurrent Hypothermia and Autonomic Dysfunction Secondary to Shapiro Syndrome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT A 44‐year‐old man presented with recurrent hypothermia, diaphoresis and hypertension. Extensive investigation for infectious, inflammatory, metabolic and endocrine aetiologies was negative. MR scan of the brain demonstrated no lesions but revealed callosal dysgenesis, consistent with Shapiro syndrome.
Naveen Kumar, Jeremy Johnson, Susanne Watkins, Eoin Mulroy   +3 more
wiley   +1 more source

A longitudinal atlas of human psoriatic skin reveals the mechanisms of anti-IL-23 therapy in disrupting the type 17 inflammatory circuit. [PDF]

Immunity
Jiang R, Blauvelt A, Shi L, Tsoi LC, Bogle R, Fox J, Gharaee-Kermani M, Chen L, Zhang H, Xing X, Sarkar MK, Plazyo O, Kahlenberg JM, Billi AC, Matheson RT, Photowala H, Ehst BD, Gudjonsson JE.   +17 more
europepmc   +1 more source

Long‐Term Efficacy of Immunotherapy in Autoimmune Autonomic Ganglionopathy—A 10‐Year Follow Up Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Autoimmune autonomic ganglionopathy (AAG) is a rare but potentially treatable cause of severe autonomic failure. Evidence guiding long‐term immunotherapy, treatment sequencing, and residual autonomic impairment is limited. We evaluated long‐term treatment response, residual autonomic dysfunction, and relapse patterns in patients with
Giacomo Chiaro, Shiwen Koay, Gordon T. Ingle, Patricia McNamara, Laura Watson, Fion Bremner, Valeria Iodice   +6 more
wiley   +1 more source

Metabolic Reprogramming of B Cells in Cancer: Effects of Altered Energetics. [PDF]

Biology (Basel)
Sarkar UA, Ambareen N, Prasad P, Kamran M, Ghosh S.   +4 more
europepmc   +1 more source

Unraveling 4‐Phenylbutyrate's Therapeutic Role in SLC6A1 Disorders: Pharmacochaperoning Over HDAC Inhibition

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Variants in SLC6A1, encoding the GABA transporter 1 (GAT‐1), cause epilepsy, autism spectrum disorder, and developmental delay via loss of GABA uptake, impaired trafficking, and ER retention. We previously found that 4‐Phenylbutyrate (PBA), an FDA‐approved drug, restores GABA uptake and reduces seizures in SLC6A1‐related disorders ...
Melissa B. DeLeeuw, Karishma Randhave, Ekta Anand, Ziang (Debbie) Song, Wangzhen Shen, Jing‐Qiong Kang   +5 more
wiley   +1 more source

COX-2 regulates IL-17A-producing γδ T cells to drive mismatch repair-deficient colon cancer

Suzuki T, White M, Leach J, Edwards J, Gilroy K, Porter R, Hong Y, Terradas-Terradas M, Hayman H, Mohamed NE, Lannagan T, Mackey J, Ridgway R, Campbell A, Verbandt S, Kirschner K, Tejpar S, Edwards J, Dunne P, Coffelt S, Sansom O.   +20 more
europepmc   +1 more source

Seasonal influenza mRNA vaccine induces stronger innate and comparable or better adaptive responses than licensed inactivated vaccines. [PDF]

NPJ Vaccines
Bermúdez-Méndez E, Lenart K, Arcoverde Cerveira R, Engstrand O, Hellgren F, Cagigi A, Ols S, Jasny E, Reinhardt A, Petsch B, Loré K.   +10 more
europepmc   +1 more source